Senate LDA lobbying filing

Eli Lilly and Company

A public disclosure record: who filed, what they reported, and the program connections found in the text.

Reported amounts Program mentions Activity text Lobbyists

Registrant: Brownstein Hyatt Farber Schreck, LLP Year: 2026 Period: First Quarter Type: Q1

Filed as: ELI LILLY AND COMPANY — BROWNSTEIN HYATT FARBER SCHRECK, LLP. Search lda.senate.gov for those strings; the names above are this site’s casing of them, nothing else.

View on lda.senate.gov ↗

Reported income

$90.0K

Reported expenses

not reported

Connections in the record

Tracked program mentions1

Making, Maintaining, Supply Chain and Logistics0602025Ematched: “Supply|Chain”matched 2+ title words
Issues related to biotechnology legislation Diagnostic tests Clinical trial issues Issues related to supply chain

Lobbying activities2

Health IssuesHCR
Issues related to biotechnology legislation Diagnostic tests Clinical trial issues Issues related to supply chain
PharmacyPHA
Issues related to the pharmaceutical industry Issues related to Inflation Reduction Act Implementation Treat and Reduce Obesity Act Pharmaceutical tariffs Safe Drugs Act

Lobbyists8

ADAM STEINMETZ
ANDREW LITTMANrevolving door
Policy Dir, Sen Barbara Boxer; Chief of Staff, Sen Al Franken; Sr Counselor, HHS Sec Sylvia Matthews Burwell
BRANDT ANDERSON
DEEMA TARAZI
EMILY FELDER
GREGORY SUNSTRUM
STEPHEN HOLLAND
ZACHARY PFISTER

Source: U.S. Senate Lobbying Disclosure Act database. Underlined dollar figures cite the filing record on lda.senate.gov and open to that citation. Amounts shown as “not reported” are absent from the filing itself.